Expression of Tolerogenic HLA-G Confer Worse Outcome in Patients with Chronic Lymphocytic Leukemia
Thabet, O., Mohamed, W., Assem, M., Abdel Hamid, A., Osman, R. (2020). Expression of Tolerogenic HLA-G Confer Worse Outcome in Patients with Chronic Lymphocytic Leukemia. EKB Journal Management System, 80(1), 587-593. doi: 10.21608/ejhm.2020.88567
Omar Elhenawy Mohamed Thabet; Wafaa Salah Mohamed; Magda Assem; Abdel Rahman Abdel Hamid; Randa Amin Osman. "Expression of Tolerogenic HLA-G Confer Worse Outcome in Patients with Chronic Lymphocytic Leukemia". EKB Journal Management System, 80, 1, 2020, 587-593. doi: 10.21608/ejhm.2020.88567
Thabet, O., Mohamed, W., Assem, M., Abdel Hamid, A., Osman, R. (2020). 'Expression of Tolerogenic HLA-G Confer Worse Outcome in Patients with Chronic Lymphocytic Leukemia', EKB Journal Management System, 80(1), pp. 587-593. doi: 10.21608/ejhm.2020.88567
Thabet, O., Mohamed, W., Assem, M., Abdel Hamid, A., Osman, R. Expression of Tolerogenic HLA-G Confer Worse Outcome in Patients with Chronic Lymphocytic Leukemia. EKB Journal Management System, 2020; 80(1): 587-593. doi: 10.21608/ejhm.2020.88567

Expression of Tolerogenic HLA-G Confer Worse Outcome in Patients with Chronic Lymphocytic Leukemia

The Egyptian Journal of Hospital Medicine
Article 6, Volume 80, Issue 1, July 2020, Page 587-593  XML PDF (712.01 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2020.88567
View on SCiNiTO View on SCiNiTO
Authors
Omar Elhenawy Mohamed Thabet email 1; Wafaa Salah Mohamed1; Magda Assem2; Abdel Rahman Abdel Hamid3; Randa Amin Osman2
1Department of Clinical Pathology, Faculty of Medicine, Aswan University
2Department of Clinical Pathology, National Cancer Institute, Cairo univeristy
3Department of Clinical Pathology, Faculty of Medicine, Qena University, Egypt
Abstract
Background: Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in adults presenting with varied clinical course. There is a higher request for founding known prognostic factors for stratifying CLL patients. HLA-G is a non-classical major histocompatibility complex (MHC) molecule. It can be expressed in membrane bound (m.HLA-G) and soluble forms (s.HLA-G). Objective: The aim of work was to investigate the expression of membrane form of HLA-G in CLL and correlate findings and a variety of clinical and laboratory variables. Patients and methods: This prospective study included a total of thirty newly diagnosed B-CLL patients, attending at Hematology Unit, Medical Oncology Department, national Cancer institute, Cairo. This study was conducted between December 2017 to July 2019. Diagnosis of CLL was confirmed by flow cytometric immunophenenotyping using standard lymphoma panel, membrane HLA-G was determined by flow cytometry. Results: The expression of HLA-G by flowcytometry was negatively correlated with the platelet count (r = -0.516, p = 0.004) and Hb (r = -0.479, p = 0.007). The expression of HLA-G was significantly higher in CD38 positive cells (p = 0.006). The expression of HLA-G was significantly higher in Rai stage 4 compared to stage 1 & stage 2 (p = 0.001). Conclusion: It could be concluded that expression of HLA-G might represent signs of immunosuppression in CLL patients which contribute to the immune escape of tumor cells. In addition, HLA-G expression by B-CLL cells correlates significantly with the known prognostic markers of disease progression, mainly Rai clinical staging, CD38 expression and worse survival, making this parameter possibly an important prognostic factors of disease progression.
Keywords
CLL; HLA-G
Statistics
Article View: 222
PDF Download: 323